The nation of Zimbabwe has turned down a substantial American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on confidential biological samples.
This move became public after a government memo dated December was disclosed, which showed President Emmerson Mnangagwa felt the agreement was "unbalanced".
A government spokesperson has since stated that the United States was demanding access to genetic material for research and profit while was not willing to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged more negotiations to find a agreement agreeable to both sides so the country's vital HIV programme can be sustained.
Wider Background
This rejection follows a similar situation in neighbouring Kenya, where a high court halted a similar health funding agreement following legal challenges were raised about the safety of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost openness and responsibility.
As per statements, Sixteen nations in Africa have so far signed similar agreements, constituting more than $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, with no equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," Mangwana explained.
"Put simply, our nation would supply the raw materials for medical research without any assurance that the resulting innovations would be accessible to our people if a future disease outbreak emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its push of one-on-one deals were undermining structures already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This system is intended to ensure that when a nation provides its information, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to further dialogue with our US partners on how future collaboration might be designed in a way that respects the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body said it acknowledged the government's concerns, but urged that talks must proceed given that a large portion of the country's HIV programmes were funded by foreign aid.
"If technical issues arise, including those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it added.
This impasse highlights the continuing debate between receiving vital international aid and safeguarding a country's data in an increasingly data-driven world.